Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 14
Submit an article Journal homepage
121
Views
3
CrossRef citations to date
0
Altmetric
Review

Advances in the medical management of Cushing's syndrome

Francesca Pecori Giraldi University of Milan, Ospedale San Luca, Istituto Auxologico Italiano, via Spagnoletto 3, 20149 Milan, Italy +39 02 619112738; +39 02 619112777; [email protected]
, MD &
Francesco Cavagnini University of Milan, Ospedale San Luca, Istituto Auxologico Italiano, via Spagnoletto 3, 20149 Milan, Italy +39 02 619112738; +39 02 619112777; [email protected]
, MD
Pages 2423-2433 | Published online: 08 Sep 2008

Bibliography

  • Invitti C, Pecori Giraldi F, De Martin M, Cavagnini F; the Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. J Clin Endocrinol Metab 1999;84:440-8
  • Biller BMK, Grossman AB, Stewart PM, et al. Treatment of ACTH-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008; doi:10.1210/:jc.2007-2734
  • Mullan KR, Atkinson AB. Endocrine clinical update: where are we in the therapeutic management of pituitary-dependent hypercortisolism? Clin Endocrinol 2007;68:327-37
  • Hoffman BM, Hlavac M, Martinez R, et al. Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 2008;108:9-18
  • Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 1997;336:172-7
  • Andrioli M, Pecori Giraldi F, De Martin M, Cavagnini F. Therapies for adrenal insufficiency. Exp Opin Ther Patents 2007;17:1323-9
  • Ilias I, Torpy DJ, Pacák K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005;90:4955-62
  • Diez JJ, Iglesias P. Pharmacological therapy of Cushing's syndrome: drugs and indications. Mini Rev Med Chem 2007;7:467-80
  • Lacroix A, N'Diaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001;22:75-110
  • Engelhardt D, Weber MM. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 1994;49:261-7
  • Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987;317:812-8
  • Stalla GK, Stalla J, Huber M, et al. Ketoconazole inhibits corticotrophic cell function in vitro. Endocrinology 1988;122:618-23
  • Castinetti F, Morange I, Jaquet P, et al. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 2008;158:91-9
  • Riedl M, Maier C, Zettinig G, et al. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 2006;154:519-24
  • Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol 1991;35:169-78
  • Hána V, Dokoupilová M, Marek J, Plavka R. Recurrent ACTH-independent Cushing's syndrome in multiple pregnancies and its treatment with metyrapone. Clin Endocrinol 2001;54:277-81
  • Halioui-Luoihaichi S, Azzabi O, Negzi L, et al. Treatment with metyrapone of Cushing's syndrome revealing McCune-Albright syndrome. Arch Pediatr 2005;12:1120-3
  • Kawashima T, Oda M, Kuno T, et al. Metyrapone for delirium due to Cushing's syndrome induced by occult ectopic adrenocorticotropic hormone secretion. J Clin Psychiatry 2004;65:1019-20
  • Drake WM, Perry LA, Hinds CJ, et al. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J Clin Endocrinol Metab 1998;83:3542-4
  • Bilgin YM, van der Wiel HE, Fischer HRA, De Herder WW. Treatment of severe psychosis due to ectopic Cushing's syndrome. J Endocrinol Invest 2007;30:776-9
  • Gärtner R, Albrecht M, Müller OA. Effect of etomidate on hypercortisolism due to ectopic ACTH production. Lancet 1986;I(8475):275
  • Allolio B, Schulte HM, Kaulen D, et al. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin Wochenschr 1988;66:361-4
  • Krakoff J, Koch CA, Calis KA, et al. Use of a parenteral propylene glycol-containing etomidate preparation of the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab 2001;86:4104-8
  • Johnson TN, Canada TW. Etomidate use for Cushing's syndrome caused by an ectopic adrenocorticotropic hormone-producing tumor. Ann Pharmacother 2007;41:350-3
  • Greening JE, Brain CE, Perry LA, et al. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Horm Res 2005;64:140-3
  • Schulte HM, Benker G, Reinwein D, et al. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990;70:1426-30
  • Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007;356:2372-80
  • Cai W, Counsell RE, Djanegara T, et al. Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharm Sci 1995;84:134-8
  • Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006;91:2650-5
  • Andrès E, Vinzio S, Goichot B, Schlienger JL. Mitotane-induced febrile pancytopenia: a first case report in paraneoplastic Cushing's syndrome. Eur J Endocrinol 2001;144:81
  • Storr HL, Mitchell H, Swords FM, et al. Clinical features, diagnosis, treatment and molecular studies in paediatric Cushing's syndrome due to primary nodular adrenocortical hyperplasia. Clin Endocrinol 2004;61:553-9
  • Kawai S, Ichikawa Y, Kaburaki J, Yoshida T. 18 years mitotane therapy for intractable Cushing's disease. Lancet 1999;354:951
  • Pliquett RU, Eichfeld U, Stumvoll M, Koch CA. Long QT syndrome under mitotane therapy. J Endocrinol Invest 2007;30:167-8
  • Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 2007;157:561-9
  • Chu JW, Matthias DF, Belanoff J, et al. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 2001;86:3568-73
  • Suda T, Tozawa F, Mouri T, et al. Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease. J Clin Endocrinol Metab 1983;56:1094-9
  • Ishibashi M, Yamaji T. Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion frum human corticotroph adenoma cells in vitro. J Clin Invest 1981;68:1018-27
  • Krieger DT, Amorosa L, Linick F. Cyproheptadine-induced remission of Cushing's disease. N Engl J Med 1975;293:893-6
  • Jimenez-Alonso J, Munoz-Avila J, Jaimez L, et al. Cyproheptadine-induced remission of Cushing's disease due to pituitary basophil adenoma. Drug Intell Clin Pharm 1982;16:962-5
  • Wiesen M, Ross F, Krieger DT. Prolonged remission of a case of Cushing's disease following cessation of cyproheptadine therapy. Acta Endocrinol (Copenh) 1983;102:436-8
  • Sonino N, Fava GA, Fallo F, et al. Effect of serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary 2000;3:55-9
  • Cartier D, Lihrmann I, Parmentier F, et al. Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. J Clin Endocrinol Metab 2003;88:248-54
  • Louiset E, Contesse V, Groussin L, et al. Expression of serotonin7 receptors and coupling of ectopic receptors to protein kinase A and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome. J Clin Endocrinol Metab 2006;91:4578-86
  • Tominaga T, Oki Y, Tanaka I, et al. Effect of sodium valproate on the secretion of proopiomelanocortin derived peptides from cultured rat anterior pituitary cells. Endocrinol Jpn 1989;36:809-15
  • Cavagnini F, Invitti C, Polli EE. Sodium valproate in Cushing's disease. Lancet 1984;2:162-3
  • Nussey SS, Price P, Jenkins JS, et al. The combined use of sodium valproate and metyrapone in the treatment of Cushing's syndrome. Clin Endocrinol 1988;28:373-80
  • Miller JW, Crapo L. The medical treatment of Cushing's syndrome. Endocr Rev 1993;14:443-58
  • Invitti C, De Martin M, Danesi L, Cavagnini F. Effect of injectable bromocriptine in patients with Cushing's disease. Exp Clin Endocrinol Diabetes 1995;103:266-71
  • Croughs RJM, Koppeschaar HPF, van't Verlaat JW, McNicol AM. Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland. J Clin Endocrinol Metab 1989;68:495-8
  • Kawamura M, Nakano T, Miki H, et al. Bromocriptine-responsive Cushing's disease;clinical and biochemical remission accompanied by amelioration of impaired ocular movement. Intern Med 2007;46:1117-22
  • Pivonello R, Ferone D, De Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004;89:2452-62
  • Godbout A, Beauregard H, Babin S, et al. Cabergoline in the long-term treatment of Cushing's disease. 89th Annual Meeting of the Endocrine Society; 2 – 5 June 2007; Toronto, Canada. p. 4-51
  • Andrioli M, Pecori Giraldi F, De Martin M, Cavagnini F. Effect of short-term, high dose cabergoline in patients with Cushing's disease. 10th International Pituitary Congress; 5 – 7 June 2007; Chicago, IL, USA. p. 48
  • Miyoshi T, Otsuka F, Takeda M, et al. Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma. J Endocrinol Invest 2004;27:1055-9
  • Petrossians P, Ronci N, Valdés Socin H, et al. ACTH silent adenoma shrinking under cabergoline. Eur J Endocrinol 2001;144:51-7
  • Yin D, Kondo S, Takeuchi J, Morimura T. Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Lett 1994;339:73-5
  • Jakubowski J. Blood supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen-induced adenomatous hyperplasia. Br J Neurosurg 1995;9:331-46
  • Farrell WE, Clark AJL, Stewart MF, et al. Bromocriptine inhibits pro-opiomelanocortin mRNA and ACTH precursor secretion in small cell lung cancer cell lines. J Clin Invest 1992;90:705-10
  • Senogles SE. D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69. Anticancer Drugs 2007;18:801-7
  • Pivonello R, Ferone D, De Herder WW, et al. Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab 2007;92:65-9
  • Reith P, Monnot EA, Bathija PJ. Prolonged suppression of a corticotropin-producing bronchial carcinoid by oral bromocriptine. Arch Intern Med 1987;147:989-91
  • Francia G, DavìMV, Montresor E, et al. Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine? J Endocrinol Invest 2006;29:358-62
  • Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2008;336:39-46
  • Rasmussen VG, Poulsen SH, Dupont E, et al. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease. J Intern Med 2008;263:90-8
  • Richardson UI, Schonbrunn A. Inhibition of adrenocorticotropin secretion by somatostatin in pituitary cell in culture. Endocrinology 1981;108:281-90
  • Reisine T. Multiple mechanisms of somatostatin inhibition of adrenocorticotropin release from mouse anterior pituitary tumor cells. Endocrinology 1985;116:2259-66
  • Luque RM, Gabete MD, Hochgeschwender U, Kineman RD. Evidence that endogenous SST inhibits ACTH and ghrelin expression by independent pathways. Am J Physiol Endocrinol Metab 2006;291:E395-403
  • Strowski MZ, Dashkevicz MP, Parmar RN, et al. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology 2002;75:339-46
  • Lamberts SWJ, Uitterlinden P, Klijn JGM. The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh) 1989;120:760-6
  • Stalla GK, Brockmeier SJ, Renner U, et al. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol 1994;130:125-31
  • Batista D, Zhang X, Gejman R, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006;91:4482-8
  • van der Hoek J, Waaijer M, van Koetsveld PM, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 2005;289:E278-287
  • Invitti C, De Martin M, Brunani A, et al. Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (sandostatin). Clin Endocrinol 1990;32:275-81
  • von Werder K, Müller OA, Stalla GK. Somatostatin analogs in ectopic corticotropin production. Metabolism 1996;45(Suppl 1):129-31
  • Diez JJ, Iglesias P. Successful treatment of ectopic Cushing's syndrome with the slow-release somatostatin analog lanreotide: Case report. Endocrinologist 1999;9:399-402
  • Uwaifo GI, Koch CA, Hirshberg B, et al. Is there a therapeutic role for octreotide in patients with ectopic Cushing's syndrome? J Endocrinol Invest 2003;26:710-7
  • Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707-16
  • Hofland LJ, van de Hoek J, Feelders RA, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005;152:645-54
  • Ben-Shlomo A, Wawrowsky KA, Proekt I, et al. Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem 2005;280:24011-21
  • Nolan LA, Schmid HA, Levy A. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rate anterior pitutary. J Clin Endocrinol Metab 2007;148:2821-7
  • Silva AP, Schoeffter P, Weckbecker G, et al. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 2005;153:R7-10
  • Zatelli MC, Piccin D, Vignali C, et al. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 2007;14:91-102
  • Hubina E, Nanzer AM, Hanson MR, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 2006;155:371-9
  • Fedele M, De Martino I, Pivonello R, et al. SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Clin Cancer Res 2007;13:2738-44
  • Boscaro M, Bertherat J, Ludlam WH, et al. The novel multi-ligand somatostatin analogue pasireotide (SOM230) is a potential medical therapy for patients with Cushing's disease: preliminary results from a phase II clinical study. 12th Meeting of the European NeuroEndocrine Association; 2006. OC7.50
  • Szende B, Kéri G. TT-232: a somatostatin structural derivative as a potent antitumor drug candidate. Anticancer Drugs 2003;14:585-8
  • Gruszka A, Kunert-Radek J, Radek A, et al. The effect of selective sst1, sst2, sst5 somatostatin receptor agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the “clinically non-functioning” pituitary adenomas in vitro. Life Sci 2006;78:689-93
  • Ren SG, Kim S, Taylor J, et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 2003;88:5414-21
  • Rocheville M, Lange DC, Kumar U, et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000;288:154-7
  • Pivonello R, Ferone D, Lamberts SWJ, Colao A. Cabergoline plus lanreotide for ectopic Cushing's syndrome. N Engl J Med 2005;352:2457-8
  • Oyen WJ, Bodei L, Giammarile F, et al. Targeted therapy in nuclear medicine – current status and future prospects. Ann Oncol 2007;18:1782-92
  • Van Essen M, Krenning EP, de Jong M, et al. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007;46:723-34
  • Davì MV, Bodei L, Ferdeghini M, et al. Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic Cushing syndrome from a metastatic gastrinoma: a promising proposal. Endocr Pract 2008;14:213-8
  • Heaney AP, Manory F, Hong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002;8:1281-7
  • Pecori Giraldi F, Scaroni C, Arvat E, et al. Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. Clin Endocrinol 2006;64:219-24
  • Ambrosi B, Dall'Asta C, Cannavò S, et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004;151:173-8
  • Hull SSA, Sheridan B, Atkinson AB. Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome. Clin Endocrinol 2005;62:259-61
  • Cannavò S, Arosio M, Almoto B, et al. Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease. Clin Endocrinol 2005;63:118-9
  • Barbaro D, Lapi P, Orsini P, et al. Pioglitazone treatment in Cushing's disease. J Endocrinol Invest 2005;28:388-9
  • Suri D, Weiss RE. Effect of pioglitazone on ACTH and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 2005;90:1340-6
  • Emery MN, Leontiou C, Bonner SE, et al. PPAR-γ expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-γreceptor. Clin Endocrinol 2006;65:389-95
  • Munir A, Song F, Ince P, et al. Ineffectiveness of rosiglitazone therapy in Nelson's syndrome. J Clin Endocrinol Metab 2007;92:1758-63
  • Andreassen M, Kristensen LØ. Rosiglitazone for prevention or adjuvant treatment of Nelson's syndrome after bilateral adrenalectomy. Eur J Endocrinol 2005;153:503-5
  • Páez Pereda M, Kovalovsky D, Hopfner U, et al. Retinoic acid prevents experimental Cushing's syndrome. J Clin Invest 2001;108:1123-31
  • Giacomini D, Páez Pereda M, Theodoropoulou M, et al. Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 2006;147:247-56
  • Castillo V, Giacomini D, Páez Pereda M, et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 2006;147:4438-44
  • Sanno N, Sugawara A, Teramoto A, et al. Immunohistochemical expression of retinoid X receptor isoforms in human pituitaries and pituitary adenomas. Neuroendocrinology 1997;65:299-306

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.